Portal de Periódicos da CAPES

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

2018; Elsevier BV; Volume: 131; Issue: 21 Linguagem: Inglês

10.1182/blood-2017-12-820910

1528-0020

Inhye E. Ahn, Mohammed Farooqui, Xin Tian, Janet Valdez, Clare Sun, Susan Soto, Jennifer Lotter, Stephanie Housel, Maryalice Stetler‐Stevenson, Constance M. Yuan, Irina Marić, Katherine R. Calvo, Pia Nierman, Thomas E. Hughes, Nakhle S. Saba, Gerald E. Marti, Stefania Pittaluga, Sarah E. M. Herman, Carsten Utoft Niemann, Lone Bredo Pedersen, Christian H. Geisler, Richard Childs, Georg Aue, Adrian Wiestner,

Immunodeficiency and Autoimmune Disorders

Key Points With 5-year median follow-up, continuous single-agent ibrutinib therapy was well tolerated with deepening of response. Previously untreated patients, even those with TP53 aberration, achieved durable responses.